Nephromag (Mertiatide)

Mertiatide, the active ingredient in Nephromag, is a therapeutic agent presented as an intravenous formulation for parenteral use. It is investigated for potential applications in renal and transplant medicine, though a specific drug class or approved therapeutic indication has not been publicly disclosed.

GNH USA supplies Nephromag as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Nephromag (Mertiatide) is currently under clinical investigation, and no approved therapeutic indications have been publicly disclosed.

Adverse reaction data for Nephromag (Mertiatide) are limited in publicly available sources.

Common Side Effects: - None reported in published literature.

Serious or Rare Side Effects: - No serious or rare adverse events have been documented publicly.

Given the limited public data, standard precautions for intravenous biologics should be observed. - Patient monitoring: observe for infusion reactions during and after administration. - Allergy assessment: screen for known hypersensitivity to peptide or protein products. - Renal function: evaluate baseline kidney parameters before initiating therapy. - Concomitant immunosuppression: assess infection risk when used with other immune‑modulating agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Interaction information for Mertiatide is not extensively documented.

Major Interactions (Avoid): - None identified in current literature.

Moderate Interactions (Monitor Closely): - Potential interaction with other immunomodulators: monitor immune status. - Caution when combined with nephrotoxic agents: assess renal function regularly. - Possible additive effect with anticoagulants: observe coagulation parameters.